JP2017512194A5 - - Google Patents

Download PDF

Info

Publication number
JP2017512194A5
JP2017512194A5 JP2016553329A JP2016553329A JP2017512194A5 JP 2017512194 A5 JP2017512194 A5 JP 2017512194A5 JP 2016553329 A JP2016553329 A JP 2016553329A JP 2016553329 A JP2016553329 A JP 2016553329A JP 2017512194 A5 JP2017512194 A5 JP 2017512194A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
fgf
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016553329A
Other languages
English (en)
Japanese (ja)
Other versions
JP6431083B2 (ja
JP2017512194A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/053624 external-priority patent/WO2015124727A1/en
Publication of JP2017512194A publication Critical patent/JP2017512194A/ja
Publication of JP2017512194A5 publication Critical patent/JP2017512194A5/ja
Application granted granted Critical
Publication of JP6431083B2 publication Critical patent/JP6431083B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016553329A 2014-02-20 2015-02-20 Fgf−18化合物の投与計画 Active JP6431083B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000600.8 2014-02-20
EP14000600 2014-02-20
PCT/EP2015/053624 WO2015124727A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (3)

Publication Number Publication Date
JP2017512194A JP2017512194A (ja) 2017-05-18
JP2017512194A5 true JP2017512194A5 (cg-RX-API-DMAC7.html) 2018-03-08
JP6431083B2 JP6431083B2 (ja) 2018-11-28

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016553329A Active JP6431083B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画
JP2016553284A Active JP6431082B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016553284A Active JP6431082B2 (ja) 2014-02-20 2015-02-20 Fgf−18化合物の投与計画

Country Status (25)

Country Link
US (2) US9724388B2 (cg-RX-API-DMAC7.html)
EP (2) EP3119417B1 (cg-RX-API-DMAC7.html)
JP (2) JP6431083B2 (cg-RX-API-DMAC7.html)
KR (2) KR102410988B1 (cg-RX-API-DMAC7.html)
CN (2) CN106232622A (cg-RX-API-DMAC7.html)
AR (2) AR099558A1 (cg-RX-API-DMAC7.html)
AU (2) AU2015220777B2 (cg-RX-API-DMAC7.html)
BR (2) BR112016018685A2 (cg-RX-API-DMAC7.html)
CA (2) CA2938793A1 (cg-RX-API-DMAC7.html)
DK (2) DK3107559T3 (cg-RX-API-DMAC7.html)
ES (2) ES2688551T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20181572T1 (cg-RX-API-DMAC7.html)
HU (1) HUE040350T2 (cg-RX-API-DMAC7.html)
IL (2) IL247083B (cg-RX-API-DMAC7.html)
LT (2) LT3119417T (cg-RX-API-DMAC7.html)
MX (2) MX2016010872A (cg-RX-API-DMAC7.html)
NZ (2) NZ723148A (cg-RX-API-DMAC7.html)
PL (2) PL3119417T3 (cg-RX-API-DMAC7.html)
PT (2) PT3119417T (cg-RX-API-DMAC7.html)
RS (2) RS57853B1 (cg-RX-API-DMAC7.html)
RU (2) RU2700582C2 (cg-RX-API-DMAC7.html)
SG (2) SG11201606502YA (cg-RX-API-DMAC7.html)
SI (2) SI3119417T1 (cg-RX-API-DMAC7.html)
WO (2) WO2015124731A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201605547B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3107592T (pt) 2014-02-20 2018-12-03 Merck Patent Gmbh Implante que compreende fgf-18
HRP20181572T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18
EP3250925B1 (en) 2015-01-29 2019-04-10 Ares Trading S.A. Immunoassays for highly positively charged proteins
KR20180115270A (ko) 2016-02-22 2018-10-22 노파르티스 아게 Fxr 효능제를 사용하는 방법
HRP20220737T1 (hr) 2017-09-29 2022-09-02 Merck Patent Gmbh Upalni biomarkeri za predviđanje odgovaranja na spoj fgf-18
US11513128B2 (en) 2017-09-29 2022-11-29 Merck Patent Gmbh Metabolic biomarkers for predicting responsiveness to FGF-18 compound
HRP20240665T1 (hr) 2018-09-10 2024-08-16 Merck Patent Gmbh Markeri korisni u strategijama obogaćivanja za liječenje osteoartritisa
EP3920959A1 (en) * 2019-02-08 2021-12-15 Merck Patent GmbH Treatment of patients at risk of rapid progression of osteoarthritis
WO2025077768A1 (en) * 2023-10-11 2025-04-17 Sichuan Real & Best Biotech Co., Ltd. Compositions and methods for treating arthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2500742C (en) * 2002-10-07 2014-02-18 Zymogenetics, Inc. Compositions of fgf-18 and hyaluronic acid for stimulating cartilage production and treating osteoarthritis
US20060009389A1 (en) 2004-07-06 2006-01-12 Moore Emma E Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use
WO2007070983A1 (en) * 2005-12-22 2007-06-28 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
BRPI0715728A8 (pt) * 2006-08-25 2018-04-03 Ares Trading Sa tratamento de distúrbios cartilaginosos
EA015644B1 (ru) * 2006-08-25 2011-10-31 Арес Трейдинг С.А. Способ лечения заболеваний хряща
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
JP6277121B2 (ja) * 2011-03-22 2018-02-07 アドヴィナス・セラピューティックス・リミテッド 置換された縮合三環式化合物、その組成物および医学的応用
PT3107592T (pt) 2014-02-20 2018-12-03 Merck Patent Gmbh Implante que compreende fgf-18
KR102437057B1 (ko) 2014-02-20 2022-08-26 메르크 파텐트 게엠베하 이식편 이식 및 조직 공학 절차에 있어서의 fgf-18
HRP20181572T1 (hr) 2014-02-20 2018-11-30 Merck Patent Gmbh Režim doziranja spoja fgf-18

Similar Documents

Publication Publication Date Title
JP2017512194A5 (cg-RX-API-DMAC7.html)
JP2017507142A5 (cg-RX-API-DMAC7.html)
JP2012193216A5 (cg-RX-API-DMAC7.html)
JP2015517488A5 (cg-RX-API-DMAC7.html)
JP2015038135A5 (cg-RX-API-DMAC7.html)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2013231087A5 (cg-RX-API-DMAC7.html)
JP2015057451A5 (cg-RX-API-DMAC7.html)
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
JP2016530280A5 (cg-RX-API-DMAC7.html)
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
RU2016137289A (ru) Схема применения соединения fgf-18
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
JP2013541583A5 (cg-RX-API-DMAC7.html)
JP2017501140A5 (cg-RX-API-DMAC7.html)
JP2017503014A5 (cg-RX-API-DMAC7.html)
EP4410295A3 (en) Use of vibegron to treat overactive bladder
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2016512247A5 (cg-RX-API-DMAC7.html)
JP2018506533A5 (cg-RX-API-DMAC7.html)
JP2021505669A5 (cg-RX-API-DMAC7.html)
JP2017061488A5 (cg-RX-API-DMAC7.html)
JP2019529569A5 (cg-RX-API-DMAC7.html)